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Introduction
Unrelated proteins containing glutamine repeat sequences 
are known to cause neurodegenerative disorders when the re-
peat-containing tracts are expanded beyond a critical threshold 
(Zoghbi and Orr, 2000). Pathogenesis of polyglutamine (polyQ) 
diseases is still poorly understood, but the fact that clinical pre-
sentation and neurodegeneration profiles do not overlap in these 
diseases indicates that the biologic specificities of each caus-
ative protein interfere with expansion-induced toxicity (Gatchel 
and Zoghbi, 2005). Machado-Joseph disease (MJD ), otherwise 
known as spinocerebellar ataxia type 3, is one such disease and 
is recognized as the most common form of dominantly inherited 
ataxia in the world (Schöls et al., 2004; Bettencourt and Lima, 
2011), involving the structural and functional compromise of 
discrete brain regions, such as the cerebellum, the pons, and the 
striatum (Alves et al., 2008b; Rüb et al., 2013).
MJD is caused by an abnormal expansion of a polyQ se-
quence contained in ataxin-3 (atx3; Kawaguchi et al., 1994), 
a protein of elusive biologic function nonetheless described as 
being involved in protein homeostasis systems, transcription 
regulation, and cytoskeleton organization (Matos et al., 2011). 
Atx3 displays deubiquitinase (DUB ) activity, which is mediated 
by a catalytic triad of amino acids localized in a globular N- 
terminal Josephin domain (JD) that also includes two binding 
sites for ubiquitin (Ub; Mao et al., 2005; Nicastro et al., 2005, 
2009). A flexible C-terminal tail comprises the polyQ tract and 
two or three ubiquitin-interacting motifs (UIM s), depending on 
the isoform (Harris et al., 2010).
PolyQ-expanded atx3 is known to cause cellular stress 
and to have an increased tendency to aggregate in vitro and in 
cultured cells, forming inclusions in MJD patients’ brains often 
localized in cell nuclei (Paulson et al., 1997b; Zoghbi and Orr, 
2000; Gales et al., 2005; Bauer and Nukina, 2009; Matos et al., 
2011; Scarff et al., 2015). Contrastingly, atx3 is ubiquitously 
expressed in diverse tissues and cell types (Trottier et al., 1998; 
Bauer and Nukina, 2009), indicating that region-specific mech-
anisms of toxicity are responsible for the localized neurodegen-
eration. The fact that cell demise targets neurons specifically 
(Trottier et al., 1998; Rüb et al., 2013) suggests that atx3 may 
play an important role in neuronal cells, which is disturbed on 
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polyQ expansion, but no function that would be specifically 
critical for neuronal survival or activity has ever been described.
The variable effects of polyQ-expanded atx3 in different 
cell types may result from diverging regulatory mechanisms 
of its properties and functions (Gatchel and Zoghbi, 2005; La 
Spada and Taylor, 2010; Takahashi et al., 2010). Tapping into 
these pathways constitutes a promising approach to the treat-
ment of MJD . In cells, proteins are frequently regulated by 
posttranslational modifications (La Spada and Taylor, 2010; 
Takahashi et al., 2010) and among them phosphorylation has 
been repeatedly described to modulate the toxicity of polyQ 
disease–related proteins (Pennuto et al., 2009). For example, 
preventing expanded ataxin-1 phosphorylation at S776 renders 
the protein unable to form aggregates and ameliorates disease 
phenotype (Emamian et al., 2003). Contrastingly, phosphoryla-
tion of huntingtin at S421 decreases aggregation and cell death 
in cell culture models (Humbert et al., 2002; Luo et al., 2005); 
mimicking this modification by mutating S421 to aspartate is 
neuroprotective in a lentiviral rat model (Pardo et al., 2006).
To date, five atx3 phosphorylation sites have been de-
scribed, all localized in the UIM s: S236 in the first UIM 
, S256 and 260/261 in the second, and S340 and 352 in the 
third UIM (Fei et al., 2007; Mueller et al., 2009). S256 is 
phosphorylated in vitro by glycogen synthase kinase 3β and 
preventing this modification enhances the aggregation of ex-
panded atx3 (Fei et al., 2007). Simulating phosphorylation of 
S236, or S340 and S352 simultaneously, leads to an increased 
atx3 nuclear localization in cell lines and enhances repression 
of atx3-regulated transcription in gene reporter assays (Muel-
ler et al., 2009). Pharmacologic inhibition of casein kinase 2, 
which was shown to phosphorylate atx3 C-terminal region, re-
duces the levels of nuclear atx3, activates atx3-regulated gene 
transcription, and decreases inclusion formation (Tao et al., 
2008; Mueller et al., 2009).
We have observed that pathogenic expansion of atx3 
causes a loss of dendrites and synapses in cultured neurons. 
Mimicking atx3 phosphorylation at S12, a novel phosphoryla-
tion site we hereby describe, reverts these effects, suggesting 
that atx3 may be functionally involved in the maintenance of 
these neuronal structures. Furthermore, we show that mutating 
S12 ameliorates aggregation, degeneration, and synapse loss 
in the brain of a MJD lentiviral rat model with striatal pathol-
ogy (Pardo et al., 2006; Alves et al., 2008b), suggesting that 
phosphorylation at this residue may constitute a therapeutic 
target for MJD treatment.
Results
PolyQ-expanded atx3 causes dendrite and 
synapse loss in rat neuronal cultures
The cytotoxicity of polyQ-expanded atx3 is contingent on the 
cellular type in which the protein is being expressed, consid-
ering that only neurons are targeted in MJD (Zoghbi and Orr, 
2000; Rüb et al., 2013). To determine if polyQ expansion of 
atx3 causes neuron-specific morphologic changes that may un-
derlie impaired survival and function, we started by comparing 
the dendritic tree of rat neuron cultures expressing human atx3 
with a pathogenic number of glutamines (84Q) or a nonpatho-
genic number of repeats (28Q). Cortical neurons, used consid-
ering the increasing evidence supporting the involvement of the 
cortex in the disease (Soong et al., 1997; Taniwaki et al., 1997; 
Murata et al., 1998; Ichikawa et al., 2001; Yamada et al., 2001; 
D’Abreu et al., 2012; Lopes et al., 2013; Pedroso et al., 2013; 
Rüb et al., 2013), were transfected with GFP -tagged human 
atx3 (Fig.  1  A), and the length of dendritic tracts of GFP - 
positive cells was measured. GFP -atx3 84Q-expressing neurons 
show a decreased total extension of dendrites, expressed as the 
sum of the length of all dendritic tracts in each cell (Fig. 1 B). 
Sholl analysis was used to evaluate dendrite complexity and 
further demonstrated that neurons expressing GFP -atx3 84Q 
display a withered dendritic tree, with less dendrites reaching 
80–160 µm from the cell body and no dendrites reaching >170 
µm (Fig. 1 C). This indicates that, in transfected cortical neu-
rons, expansion of GFP -atx3 causes dendritic loss or shrinkage.
We then tested whether atx3 expansion affected synap-
tic contacts established between the cultured neurons. Visu-
alization of functional excitatory glutamatergic synapses was 
achieved by colocalizing the punctuate signal of pre- and post-
synaptic protein markers: the vesicular glutamate transporter 
subtype 1 (VGL UT1) and postsynaptic density protein 95 (PSD 
-95; Fig. 1 D). Compared with neurons transfected with GFP 
-atx3 28Q, neurons expressing GFP -atx3 84Q have a significant 
reduction in the number of glutamatergic synapses (Fig. 1 E). 
Similar differences were detected for inhibitory postsynaptic 
terminals, as evaluated by the number of gephyrin-positive 
puncta (Fig. 1, F and G).
Importantly, compared with neurons expressing the empty 
GFP vector, cells transfected with GFP -atx3 28Q show no dif-
ferences in any of the parameters analyzed, underscoring the 
role of the polyQ expansion of GFP -atx3 in the phenotypes ob-
served (Fig. S1). Results therefore indicate that polyQ expan-
sion of atx3 in transfected cultured neurons causes morphologic 
defects in neuron-specific structures.
Atx3 is phosphorylated at S12 in 
mammalian neurons
We moved on to explore novel phosphorylation sites of atx3 
that could account for the modulation of toxicity of the pro-
tein, starting by a mass spectrometry analysis directed at phos-
phorylation site detection. GFP -atx3 28Q was purified from 
transiently transfected HEK 293FT cells by immunoprecipi-
tation and SDS -PAG E (Fig. 2 A), and peptides resulting from 
tryptic digestion of the GFP -atx3 bands were separated by 
reverse-phase high performance liquid chromatography and 
electrosprayed into the mass spectrometer. Examination of the 
protein sample produced from okadaic acid–stimulated cells re-
vealed the presence of one phosphorylated peptide and mapped 
S12 as the modified residue (Fig. 2 B).
We then generated a phosphospecific antibody recognizing 
atx3 phosphorylated at S12 (anti-Patx3; Fig. 2 C) and used it to 
probe extracts from cultured rat cortical neurons. Western blot 
analysis yielded a band with the molecular weight expected of 
endogenous rat atx3 (Fig. 2 D), which is absent when the protein 
is knocked-down in cultures transduced with lentiviral vectors 
encoding atx3-targeting shRNA s (Alves et al., 2010). Bands of 
lower molecular weight yielded by the anti-Patx3 antibody possi-
bly correspond to endogenous atx3-derived fragments mentioned 
in other studies (Berke et al., 2005; Pozzi et al., 2008; Koch et al., 
2011; Simões et al., 2012). Higher molecular weight endogenous 
atx3 protein bands have also been observed in previous studies 
(Paulson et al., 1997a; Trottier et al., 1998; Koch et al., 2011). 
Neuronal extracts prepared in the absence of phosphatase inhib-
itors display decreased immunoreactivity, supporting that the 
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anti-Patx3 antibody is labeling phosphorylated atx3 (Fig. 2 E). 
The analysis of Patx3 labeling in MJD patient’s fibroblasts and in 
fibroblasts of a healthy control (Fig. 2, F and G) revealed a pro-
tein band pattern similar to that observed in cultured rat neurons, 
indicating that atx3 is phosphorylated in human samples.
Our observations indicate that S12 is a phosphor-
ylation site of endogenous atx3 and that phosphate con-
jugation to this residue occurs normally in cultured rat 
neurons and human fibroblasts.
Mimicking S12 phosphorylation decreases 
atx3 DUB activity in vitro
S12 is localized in the catalytic JD (aa 8–168), the N-terminal do-
main of atx3 (Masino et al., 2003; Almeida et al., 2013; Fig. 3 A). 
In the solution structure of atx3 JD (Nicastro et al., 2005), S12 
is located at the cleft between the globular catalytic subdomain 
and the flexible helical hairpin predicted to play a role in sub-
strate recognition (Komander et al., 2009; Nicastro et al., 2009). 
S12 is located in the loop preceding helix α1, where C14, the 
nucleophile of the catalytic triad, is located, and nearby Q9, the 
residue proposed to contribute to the stabilization of the nega-
tively charged transition state during peptide bond cleavage 
(Nicastro et al., 2005; Fig. 3 B). S12 is also adjacent to the loop 
centered on S72, which precedes the helical hairpin that com-
prises the docking site for the C terminus of the Ub substrate 
(Nicastro et al., 2009; Fig. 3, C and D). S12 is exposed to the 
solvent on the surface of the JD and is consequently accessible 
for phosphate conjugation. The proximity of S12 to structural el-
ements associated to substrate binding and hydrolysis suggests 
that phosphorylation at this residue affects atx3 DUB activity.
We investigated the effect of S12 phosphorylation on 
atx3 enzymatic activity using in vitro DUB assays. A mutant 
of hexahistidine (6His)-atx3 with S12 substituted by a nega-
tively charged aspartate, 6His-atx3 S12D, was generated to 
mimic constitutive phosphorylation. Because 6His-atx3 wild 
type (WT) and 6His-atx3 S12D were expressed in Escherichia 
coli, nonmutated His-atx3 WT is not phosphorylated. After pu-
rifying the proteins through a series of chromatographic steps as 
Figure 1. PolyQ expansion of atx3 causes dendrite and synapse loss in cortical neurons. (A) Rat cortical neuron cultures were transfected with nonex-
panded GFP -atx3 28Q and expanded GFP -atx3 84Q. The panel shows representative fluorescence microscopy images of the cell body and dendritic tree. 
Bars, 100 µm. (B) Neurons expressing GFP -atx3 84Q WT display a reduced total length of dendritic tracts (n = 19–21, from two independent experiments; 
t test: **, P < 0.01). (C) Sholl analysis reveals a contraction of dendrites caused by GFP -atx3 84Q expression, comparing with neurons expressing GFP 
-atx3 28Q (n = 19–21 neurons, from two independent experiments; t test: *, P < 0.05; **, P < 0.01). (D) Excitatory synapses were immunocytochemically 
detected as instances of PSD -95 and VGL UT1 puncta colocalization (merge); (F) inhibitory postsynaptic terminals were quantified as gephyrin-positive 
puncta. Panels show representative fluorescence microscopy images of dendritic tracts evidencing synaptic marker puncta. Bars, 5 µm. (E and G) Expres-
sion of GFP -atx3 84Q causes a decrease in the number of excitatory synapses (n = 31–32 neurons, from three independent experiments; t test: ***, P < 
0.001) and inhibitory postsynaptic terminals (n = 30–31 neurons, from three independent experiments; t test: ***, P < 0.001), compared with expression 
of GFP -atx3 28Q. (B, C, E, and G) Graph bars represent mean ± SEM .
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previously described (Gales et al., 2005), they were incubated 
with the substrate Ub-C-terminal 7-amino-4-methylcoumarin 
(Ub-AMC ), and the fluorescence yielded by free AMC was re-
corded as a measure of product formation. The respective reac-
tion curves reveal that the substrate cleavage rate is higher for 
6His-atx3 WT comparing with the phosphomimetic 6His-atx3 
S12D (Fig. 4 A). The decreased activity of the phosphomimetic 
form is expressed by a 43.6 ± 4.7% (SEM ) reduction of the initial 
reaction velocity, when compared with the control (Fig. 4 B).
Incubation of 6His-atx3 WT or 6His-atx3 S12D with 
K48- and K63-linked chains of six Ub monomers led to the 
formation of Ub species of lower molecular weight in a time- 
dependent manner, as assessed by Western blot (Fig. 4, C–F). 
Consistent with a reduced substrate proteolysis, 6His-atx3 
Figure 2. S12 of atx3 is phosphorylated in neurons. (A) HEK 293FT cells were transfected with GFP -atx3 28Q and stimulated with phorbol-12-myristate 
13-acetate (PMA ), sodium orthovanadate (SOV ), or okadaic acid (OA) to increase protein phosphorylation levels. GFP -atx3 28Q was immunoprecipitated, 
separated by SDS -PAG E, and the resulting gel was stained with Coomassie blue, as represented. GFP -atx3 28Q bands (marked with *) were excised and 
subjected to tryptic digestion and mass spectrometry analysis. (B) Online liquid chromatography followed by ion spray mass spectrometry (LC-ES-MS) de-
tected one phosphorylated peptide in the sample prepared after okadaic acid stimulus and mapped the phosphorylation site to S12. Human atx3 variant 
MJD 1a amino acid sequence (available from GenBank under accession no. AAB33571.1) is shown with the detected phosphopeptide colored in red. 
(C) A phosphospecific antibody recognizing phosphorylated atx3 S12 was produced. The diagram represents the positions of the S12-containing antigen 
used during antibody production and the epitope recognized by the anti-atx3 antibody (clone 1H9). (D) Western blot probing of cortical neuron lysates with 
the anti-Patx3 antibody yielded a protein band corresponding to full-length endogenous atx3 that is absent from cells transduced with atx3-targeting shRNA 
(sRNA -atx3). Actin was used as a loading control. (E) The endogenous atx3 band displays no immunoreactivity when cell lysates are prepared without 
phosphatase (PP) inhibitors. (F) Probing of human MJD patient fibroblasts (MJD 1–3) and a matched control with the anti-Patx3 antibody reveals a similar 
protein band pattern to that of neurons. exp., expanded; nonexp., nonexpanded. (G) Increased resolving of patient MJD 2 fibroblast sample distinguishes 
two bands that match the size of expanded (exp.) and nonexpanded (nonexp.) atx3.
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S12D elicited a decreased formation of Ub products compar-
ing with 6His-atx3 WT. This was observed for both types of 
chains; however, the difference is more prominent in the reac-
tion with the K63-linked chains.
Collectively, these in vitro assays demonstrate that the 
presence of a negatively charged aspartate at position 12 de-
creases atx3 DUB activity, suggesting that such is the effect of 
S12 phosphorylation on atx3 DUB activity.
Mimicking S12 phosphorylation counters 
morphologic changes caused by expression 
of pathogenic atx3 in neuronal cultures
We tested whether phosphorylation of S12 interfered with the 
neuromorphologic defects caused by expanded atx3 expression 
in cortical neurons. Cultures were transfected with phosphomi-
metic GFP -atx3 84Q S12D or nonphosphorylatable GFP -atx3 
84Q S12A (Figs. 5 A and S2), and total dendritic length was 
analyzed aspreviously described (see first pragraph of Results). 
The GFP -atx3 84Q S12A mutant exhibited similar effects to 
those of GFP -atx3 84Q WT, but neurons expressing GFP -atx3 
84Q S12D had higher total dendritic length, showing no differ-
ences relative to the total dendritic length of cells expressing 
GFP -atx3 28Q WT (Fig. 5, A and B). Nonexpanded GFP -atx3 
28Q S12A also led to an increased toxicity comparing with the 
other nonexpanded forms. These results suggest that phosphor-
ylation of S12 protects against dendritic tract loss caused by 
atx3 polyQ expansion and that compromising this modification 
is enough to cause a loss of dendritic tracts.
We then investigated whether the S12 phosphomutations 
affected the number of synaptic contacts in the cultures. Neurons 
expressing GFP -atx3 84Q S12D show no difference in the num-
ber of excitatory glutamatergic synapses (Fig. 6, A and C) and in-
hibitory postsynaptic terminals (Fig. 6, B and D) compared with 
GFP -atx3 28Q WT, suggesting that atx3 phosphorylation at S12 
rescues the deleterious outcomes of expanded atx3 expression.
The differential effects caused by mutation of S12 
hint to the fact that phosphorylation of this amino acid resi-
due counters the morphologic defects caused by expanded 
atx3 expression in neurons.
Atx3 S12 modulates toxicity induced 
by pathogenic atx3 in cultured neurons 
and in vivo
Given the recognized role of aggregation in the toxicity path-
ways involved in polyQ expansion diseases, we tested whether 
the S12 phosphomutations affected atx3 tendency to aggregate. 
It has been demonstrated that atx3 JD is prone to self-assemble 
in vitro, modulating aggregation of both expanded and nonex-
panded atx3 (Masino et al., 2004, 2011; Gales et al., 2005; El-
lisdon et al., 2006); changes caused by phosphorylation at S12 
could therefore modulate the dynamics of atx3 aggregation.
Cortical neurons were transfected with GFP -tagged WT or 
phosphomutants S12D or S12A atx3 and scanned in search for 
GFP -positive accumulations. Cells were counted as having GFP 
-atx3 aggregation when they presented at least one noticeable 
instance of GFP -positive accumulation, regardless of size; cells 
Figure 3. S12 localizes in the vicinity of atx3 catalytic site. (A) S12 (yellow) is positioned in the groove between the two subdomains of the JD, (B) in 
close proximity to the amino acids of the catalytic triad—C14, H119, and N134—and to the residue proposed to form the oxyanion hole—Q9 (PDB ID 
1YZB; Nicastro et al., 2005). (C and D) Binding of an Ub molecule to the Ub-binding site 1 of the JD positions the C-terminal region of Ub close to S12 
(PDB ID 2JRI; Nicastro et al., 2009). The structures represented in (A–D) were prepared with PyMOL (http ://www .pymol .org). (E) S12 (arrowhead) is 
conserved in vertebrate atx3 but is substituted by a phenylalanine residue in atx3L and by a glutamate residue in Josephin-1 and -2. Protein sequences 
were obtained from the UniProt database, aligned with the Crustal Omega online tool (http ://www .ebi .ac .uk /Tools /msa /clustalo /) and displayed with 
ESP ript 3.0 (Robert and Gouet, 2014). Strictly conserved residues are represented by white letters in a black background and highly similar residues are 
represented by bold letters in framed columns.  o
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displaying only diffuse GFP signal were counted as having no 
aggregates (Fig. 7 A). Expanded GFP -atx3 84Q WT displays 
a profoundly increased tendency to aggregate compared with 
GFP -atx3 28Q WT (Fig. 7 B), as expressed by the percentage 
of cells that presented aggregates in the context of the overall 
population of transfected cells (GFP -atx3 aggregates in 48.31 
± 10.25% of the cells; n = 5). This is in agreement with the 
well-known association between the tendency to aggregate and 
the length of the polyQ sequence, serving as validation to this 
aggregation assay. Mutation of S12 to aspartate or alanine de-
creases the fraction of neurons with aggregates, reaching statis-
tical significance in cells transfected with GFP -atx3 84Q S12A 
(Fig. 7 B). The results suggest that S12 contributes to atx3 ag-
gregation and toxicity in neurons and that modification of this 
amino acid decreases these effects. The DUB inactive mutant 
GFP -atx3 84Q C14A (Burnett et al., 2003) exhibits a tendency 
to aggregate comparable with that of GFP -atx3 84Q WT (Fig. 
S3), suggesting that the effect of atx3 phosphorylation on atx3 
aggregation is not related to its effect on proteolytic activity.
Finally, we explored the changes caused by S12 phosphor-
ylation on the pathogenic events occurring on a lentiviral ani-
mal model of MJD with striatal pathology, generated by direct 
delivery of viral particles encoding full-length human expanded 
atx3 (72Q) to the striatum of adult animals by stereotaxic injec-
tion (Alves et al., 2008b). For each animal, particles encoding 
atx3 72Q WT were injected into the striatum of the brain’s left 
hemisphere, whereas the striatum of the right hemisphere was 
injected with particles encoding either atx3 72Q S12D or atx3 
72Q S12A (Figs. 8 A and S4). Animals were euthanized 4 wk 
after injection, and coronal brain slices of the whole striatal re-
gion were immunohistochemically processed and analyzed.
Slices were labeled with an anti-atx3 antibody, and the 
regions of the striatum demonstrating atx3 aggregation were 
imaged and the number of inclusions was quantified (Alves et 
al., 2008a; Nascimento-Ferreira et al., 2011). Transduction of 
the rat striatum with atx3 72Q led to the formation of detect-
able aggregates (Fig. 8, B and C), in agreement with what has 
been described for this animal model. Mutation of S12 to aspar-
tate or alanine significantly decreased the amount of inclusions 
formed, comparing with atx3 72Q WT (Fig. 8, F and G).
Examination of the severity of neurodegeneration caused 
by each atx3 72Q form was performed by labeling the slices 
with an antibody detecting a neuronal marker: dopamine- and 
cyclic AMP -regulated phosphoprotein of 32 kD (DAR PP-32). 
Expression of atx3 72Q led to a localized loss of anti–DAR 
PP-32 antibody immunoreactivity, compatible with the toxicity 
expected of atx3 with a pathogenic polyQ expansion (Fig.  8, 
D and E). Nonetheless, the volume of the DAR PP-32–depleted 
region was reduced in the case of the injections with the phos-
phomutants, comparing with atx3 72Q WT (Fig. 8, H and I).
Excitatory synapses were labeled in striatal slices with 
antibodies detecting the postsynaptic protein PSD -95 and the 
presynaptic vesicular transporter VGL UT1, and the immunore-
activity signal of each marker was imaged in the vicinity of atx3 
72Q–expressing neurons (Fig. 8, J, L, N, and P). The integrated 
density of PSD -95 and VGL UT1 agglomerates was quantified 
through a range of detection thresholds and found to be in-
creased in the striatal slices expressing phosphomutated (S12A 
or S12D) atx3 72Q, comparing with slices expressing atx3 72Q 
WT (Fig. 8, K, M, O, and Q), suggesting that phosphorylation 
of S12 decreases excitatory synapse loss associated with the ex-
pression of expanded atx3 in the rat striatum.
Figure 4. Mimicking S12 phosphorylation decreases atx3 DUB activity in vitro. (A) Recombinant 6His-atx3 was incubated with Ub-AMC in vitro, and 
product formation was assessed by measuring AMC fluorescence. 6His-atx3 S12D shows a decreased Ub-AMC cleavage rate, comparing with 6His-atx3 
WT. The panel shows the reaction curve of initial product formation of a representative experiment (n = 3 technical replicates, dots represent mean ± SEM 
fluorescence values, after subtracting the value of buffer and Ub-AMC only; RFU , relative fluorescence units; two-way ANO VA detected a P < 0.0001 
significant difference between protein samples). (B) The initial reaction velocity of 6His-atx3 S12D is decreased to 43.6 ± 4.7% in relation to 6His-atx3 WT 
(n = 8 technical replicates normalized to 6His-atx3 WT, from three independent experiments; graph bars represent mean ± SEM ; t test: ***, P < 0.001). 
(C and E) In vitro incubation of 6His-atx3 with K48- or K63-linked hexameric polyUb chains (6Ub) leads to a time-dependent formation of lower molecular 
weight Ub species (Ub2–5), as assessed by Western blot labeling of Ub species. 6His-atx3 S12D elicits less polyUb cleavage than 6His-atx3 WT. (D and 
F) PolyUb chains showed no time-dependent degradation in the absence of 6His-atx3.
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The observations made in the MJD lentiviral rat model 
indicate that phosphomutation of S12 decreases expanded atx3 
aggregates and cytotoxicity, in vivo.
Discussion
Approaches to MJD treatment may benefit from a deepened 
comprehension of the reversible pathways that interfere with 
the cellular defects caused by pathogenically expanded atx3. 
This study demonstrates that polyQ expansion of the protein 
causes a loss of dendrites and synapses that is countered by sim-
ulating phosphorylation of the protein at S12. Importantly, mu-
tation of this novel phosphorylation site reduces the tendency 
of pathogenic atx3 to aggregate and induce neuronal demise in 
vivo, suggesting that phosphorylation of S12 of atx3 may have 
a protective effect in the context of MJD (Fig. 9).
The phosphospecific anti-Patx3 antibody that was gen-
erated detected phosphorylated atx3 in cortical neurons and 
human fibroblasts for the first time, indicating that phosphory-
lation of S12 is physiologically relevant. We investigated neu-
ron-specific changes in cellular morphology in cortical cultures, 
considering the growing evidence implicating the cerebral cor-
tex in the pathogenic mechanisms (Yamada et al., 2001; Alves 
et al., 2008b; Pedroso et al., 2013; Rüb et al., 2013): authors 
have described reduced glucose metabolism (Soong et al., 
1997; Taniwaki et al., 1997) and atrophy in the cortex of MJD 
patients’ brain (Murata et al., 1998; D’Abreu et al., 2012; Lopes 
et al., 2013) and the presence of polyQ inclusions (Yamada et 
al., 2001; Ishikawa et al., 2002). Although cortical neurons are 
not frequently found to visibly degenerate, it is possible that 
they are dysfunctional in MJD ; the presence of inclusions may 
reflect this dysfunction, even if it is not causatively involved 
(Schöls et al., 2004). In our experiments, the presence of an 
expanded polyQ sequence in transfected GFP -atx3 led to a mor-
phologic phenotype, with contracted dendrites, fewer excitatory 
synapses, and a decreased number of inhibitory postsynaptic 
terminals. Previous studies using neurons from transgenic Dro-
sophila larvae have detected dendritic abnormalities result-
ing from expanded atx3 expression (Lee et al., 2011), and a 
severe impairment of dendritic arborization was also recently 
described to occur in the Purkinje cells of a MJD mouse model 
(Konno et al., 2014). Our results constitute the first evidence that 
full-length expanded atx3 causes an observable dendritic loss/
shrinkage and synapse loss in mammalian neuron cultures, sug-
gesting that similar events may take place in MJD patient brains. 
The changes we observe may also occur in brain regions other 
than the cortex, representing a wider neuronal-specific mech-
anism of cellular dysfunction. The possibility of a disruption 
of neuronal structure—and, consequently, function—without or 
before cell death triggering supports the prevalent idea of an in-
volvement of synaptic dysfunction in the pathogenesis of MJD 
(Chou et al., 2008; Boy et al., 2010; Shakkottai et al., 2011).
Mutation of S12 to negatively charged aspartate reduced 
the dendritic demise and synaptic loss caused by polyQ-ex-
panded atx3 expression in cortical neurons; contrastingly, the 
effects of the phospho-null mutant were similar to those of the 
nonmutated expanded atx3. These results suggest that phos-
phorylation at S12 may be able to counter the cellular defects 
caused by atx3 expansion. Additionally, the fact that these 
defects are reversible on mutation of a single residue, which 
is distant from the polyQ stretch, suggests that atx3 may be 
functionally involved in the development or maintenance of 
dendrites and synapse in vivo. Our results suggest that S12 
phosphorylation contributes to this function, which would be 
disrupted on polyQ expansion. Thus far, atx3 has never been 
demonstrated to play any clear function which would be critical 
for neuronal survival and activity, but it was recently reported to 
be involved in neuronal differentiation of neuroblastoma cells 
(Neves-Carvalho et al., 2015). Atx3 involvement with dendrite 
and synapse maintenance may be mediated through its reported 
participation in cell pathways, including transcriptional regula-
tion (Rodrigues et al., 2007; Chou et al., 2008), protein quality 
control, and cytoskeletal organization (Rodrigues et al., 2010). 
Future studies will be needed to determine if dendrite retraction 
and synaptic loss on atx3 expansion result from the disturbance 
of any of these functions.
Figure 5. Mimicking S12 phosphorylation reduces dendritic tract loss 
caused by expression of expanded atx3 in cortical neurons. (A) Rat cortical 
neuron cultures were transfected with phosphomutants S12D and S12A of 
GFP -atx3 28Q and GFP -atx3 84Q. Panels show representative fluores-
cence microscopy images of the cell body and dendritic trees of trans-
fected neurons. Bars, 100 μm. (B) Expression of phospho-null GFP -atx3 
84Q S12A causes a reduction of total dendritic length, but transfection 
with GFP -atx3 84Q S12D elicits no differences, comparing with the GFP 
-atx3 28Q WT control (n = 16–21 neurons, from two independent experi-
ments; graph bars represent mean ± SEM ; comparison with GFP -atx3 28Q 
WT was performed with the Mann-Whitney t test: **, P < 0.01; ***, P < 
0.001; two-way analysis of variance followed by Bonferroni post hoc test 
compared between other pairs of conditions: #, P < 0.05).
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The in vitro assays show that S12 phosphorylation reg-
ulates atx3 DUB activity, adding to the previously described 
effect of ubiquitination of K117 at the JD, which enhances the 
DUB activity of the protein (Todi et al., 2010). In the cell envi-
ronment, conjugation of a phosphate group to S12, localized in 
the catalytic domain of atx3, might affect the neighboring amino 
acid residues, as a consequence of steric constraints and/or im-
posed by the negative charge of the phosphate group. Changes 
in the amino acids comprising the catalytic triad or alterations 
that could affect substrate binding and/or positioning, such as 
in the conformation of the closely positioned Ub-binding site 
1 of the JD helical hairpin, might result in changes of proteo-
lytic activity (Nicastro et al., 2005, 2009; Hunter, 2007; Tarrant 
and Cole, 2009; Huang et al., 2012; Renatus and Farady, 2012). 
Notably, the crystal structure of the complex formed by Ub and 
the ataxin-3–like protein (atx3L) JD revealed that the phenylal-
anine at position 12 forms a hydrophobic enclosure with other 
aromatic amino acid around the active center, through which the 
C terminus of the Ub molecule threads (Weeks et al., 2011). The 
position appears to be suitable for interaction with the lysine 
side chain forming the isopeptide bond. It has been reported 
that mutation of S12 of the atx3 JD to a phenylalanine increases 
proteolysis of Ub substrates (Weeks et al., 2011), consistent 
with the relevance of this residue in determining atx3 activity 
that our results propose. Phosphorylation of S12 may therefore 
modulate important aspects of atx3 biologic activity, such as 
the cleavage rate of particular atx3 substrates and/or the molec-
ular interactions established by the protein. The consequences 
of these changes may have different cellular outcomes, possibly 
related to the maintenance of specialized neuronal structures.
S12 is highly conserved in atx3 vertebrate homologues, but 
is substituted by different residues in other JD-containing proteins: 
a negatively charged glutamate in Josephin-1 and -2 and an aro-
matic phenylalanine in atx3L (Fig. 3 E). In agreement with our 
results showing that S12 phosphorylation decreases the proteolytic 
activity of atx3, the activity of the JDs isolated from human atx3, 
atx3L, Josephin-1, and Josephin-2 has been shown to be markedly 
different when tested against several different Ub model substrates 
in vitro (Weeks et al., 2011). Although the variations reported may 
be attributed to other sequence or structural differences between 
the protein JDs, it is possible that the residue occupying the posi-
tion of S12 plays a role in modulating enzyme activity.
Figure 6. Mimicking S12 phosphorylation reduces 
synapse loss elicited by expanded atx3 expression in 
cortical neurons. (A and B) Rat cortical neuron cul-
tures were transfected with phosphomutants S12D 
and S12A of GFP -atx3 28Q and GFP -atx3 84Q. The 
panels show representative fluorescence microscopy 
sections from dendritic tracts of GFP -atx3–express-
ing neurons, evidencing (A) glutamatergic synapse 
markers VGL UT1 and PSD -95–positive puncta and the 
respective colocalization (merge) or (B) gephyrin-posi-
tive puncta. Bars, 5 μm. (C) Expression of the GFP -atx3 
84Q S12A mutant causes a decrease in the number 
of functional glutamatergic synapses, comparing with 
the expression of GFP -atx3 28Q WT. Phosphomimetic 
GFP -atx3 84Q S12D causes no significant reduction 
(n = 24–32 neurons, from three independent experi-
ments; graph bars represent mean ± SEM ; compari-
son with GFP -atx3 28Q WT was performed with the 
Mann-Whitney t test: **, P < 0.01; ***, P < 0.01; 
two-way analysis of variance followed by Bonferroni 
post hoc test compared between other pairs of condi-
tions: #, P < 0.05; ##, P < 0.01). (D) GFP -atx3 84Q 
S12D expression does not produce the loss of inhibi-
tory postsynaptic terminals caused by GFP -atx3 84Q 
WT and S12A, as inferred from the number of gephy-
rin-containing puncta (n = 24–30 neurons, from three 
independent experiments; graph bars represent mean 
± SEM ; comparison with GFP -atx3 28Q WT was per-
formed with the Mann-Whitney t test: ***, P < 0.001; 
two-way analysis of variance followed by Bonferroni 
post hoc test compared between other pairs of con-
ditions: ###, P < 0.001).
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Mutation at serine 12 to aspartate or alanine reduces 
the tendency of expanded GFP -atx3 to form aggregates in 
cultures neurons. It has been hypothesized that atx3 aggrega-
tion is dependent on the molecular interactions it establishes, 
and in vitro association of the JD with Ub protects against 
aggregation (Song et al., 2010; Masino et al., 2011). The two 
Ub-binding sites in the catalytic JD overlap with the regions 
described as taking part in JD self-assembly (Nicastro et al., 
2009; Masino et al., 2011), and interestingly, S12 is in close 
proximity to the Ub-binding site 1. Taking all this into con-
sideration, mutation at S12 may reduce aggregation by in-
terfering with the interactions modulated by Ub-binding site 
1, possibly favoring interactions that protect against atx3 ag-
gregation. The fact that the inactive C14A mutant leads to an 
aggregation profile similar to that of GFP -atx3 84Q supports 
the idea that this effect on aggregation is not related to the 
decrease in DUB activity caused by phosphorylation. Further-
more, phosphomutation of S12 does not alter atx3 subcellular 
localization (in COS -7 cells; Fig. S5, A–D), indicating that the 
decrease on aggregation may not involve a decreased nuclear 
distribution of the protein.
When the phosphomutants of atx3 are expressed in the 
striatum of injected rats, they lead to a decreased inclusion for-
mation and neurodegeneration comparing with the nonmutated 
protein, suggesting that S12 modification has a protective effect 
in vivo. This similar effect of the phosphomimetic and the phos-
pho-null mutations is not unique. In a study describing the effects 
of huntingtin phosphorylation at T3, although each phosphomu-
tant of T3 had opposed tendencies to aggregate, both mutations 
were neuroprotective in a Drosophila model, reducing lethality 
and neurodegeneration (Aiken et al., 2009). Our results indicate 
that the availability of S12 is an important factor contributing to 
toxicity-related events in neurons. We suggest that nonphosphor-
ylated S12 of expanded atx3 may contribute to pathways turning 
the protein more toxic, precipitating events such as misfolding, 
cleavage, or aggregation. Consequently, modifications targeting 
S12 may reduce the toxicity of expanded atx3, with possible pro-
tective outcomes. In a biologic context, the modifications caused 
by phosphorylation of S12 are likely to influence pathogenic 
mechanisms mediated by this amino acid. Phosphorylation of 
S12, as a biologic device that actually turns it into a different 
chemical entity, could have an effect of “turning off” the toxic 
mechanisms in which S12 takes part.
The ameliorating effects of the phosphomimetic muta-
tions in our cell culture and in vivo models of MJD strongly 
suggest that S12 phosphorylation is protective against the 
toxicity of expanded atx3. Further studies will inform on the 
usability of the modulation of S12 phosphorylation state as a 
target for MJD therapy.
Materials and methods
Expression plasmids and lentiviral vectors
Eukaryotic expression pEGF P-C1 plasmids encoding human atx3 vari-
ant MJD 1a (available from GenBank under accession no. AAB33571.1) 
with 28 glutamines (GFP -atx3 28Q) or 84 glutamines (GFP -atx3 28Q) 
N terminally fused with GFP (Chai et al., 1999) and pFLA G-CMV -6a 
plasmids encoding human atx3 variant MJD 1-1 (available from Gen-
Bank under accession no. NP_004984.2) with 22 glutamines (FLA 
G-atx3 22Q) or 80 glutamines (FLA G-atx3 80Q) N terminally fused 
with FLA G were a gift from H. Paulson (University of Michigan, Ann 
Arbor, MI). Empty vector pEGF P-C1 was obtained from BD Biosci-
ences (available from GenBank under accession no. U55763). Eukary-
otic expression plasmid SIN -W-PGK encoding human atx3 variant 
MJD 1a with 72 glutamines and an N-terminal Myc tag (atx3 72Q) 
and plasmid SIN -CW-PGK -nls-LacZ-LTR -TRE encoding an universal 
short hairpin targeting human and rat atx3 (shRNA -atx3) were previ-
ously produced by our group (Alves et al., 2008b, 2010). Constructs 
used in the viral production (pCMV DR-8.92, pMD.G, and pRSV -Rev) 
have been described previously (de Almeida et al., 2002) and were 
a gift from N.  Deglon (University Hospital of Lausanne, Lausanne, 
Switzerland). Bacterial expression pDES T17 plasmid encoding N-ter-
minally 6His-tagged human atx3 isoform MJD 1-1 with 13 glutamines 
(6His-atx3) was previously generated by our group (Gales et al., 2005).
Site-directed mutagenesis of the expression constructs was 
performed using the QuickChange Site-Directed Mutagenesis kit 
(Stratagene) or the QuikChange II XL Site-Directed Mutagenesis kit 
(Agilent Technologies). Phosphomimetic S12D mutants, with aspartate 
at position 12, were generated using primers (forward) 5′-CAC GAG 
AAA CAA GAA GGC GAC CTT TGT GCT CAA CAT TGC CTG -3′ and 
(reverse) 5′-CAG GCA ATG TTG AGC ACA AAG GTC GCC TTC TTG 
TTT CTC GTG -3′. Phospho-null S12A mutants, with alanine at posi-
Figure 7. Mutating S12 decreases expanded atx3 aggregation in cor-
tical neurons. (A) GFP -atx3 accumulates in the cell body of a fraction of 
transfected cortical cultures. The number of cells with GFP -atx3 aggre-
gates was counted versus the number of cells presenting only diffuse GFP 
-atx3 signal; neurons displaying a compromised structure were excluded 
from the counting. The panels illustrate the diversity of the aggregates ob-
tained. Bar, 20 μm. (B) Mutating S12 of GFP -atx3 84Q decreases the 
fraction of cells with aggregates comparing with what is caused by GFP 
-atx3 84Q WT. The decrease reaches statistical significance with GFP -atx3 
84Q S12A (17–59 neurons were counted for each condition in n = 5 
independently prepared cultures; graph bars represent mean ± SEM ; one- 
sample t test: **, P < 0.01).
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tion 12, were obtained with primers (forward) 5′-CAC GAG AAA CAA 
GAA GGC GCA CTT TGT GCT CAA CAT TGC CTG -3′ (reverse) 5′-
CAG GCA ATG TTG AGC ACA AAG TGC GCC TTC TTG TTT CTC GTG 
-3′. DUB activity-deficient C14A mutants, with alanine at position 14, 
were produced with primers (forward) 5′-GAG AAA CAA GAA GGC 
TCA CTT GCT GCT CAA CAT TGC CTG -3′ and (reverse) 5′-CAG GCA 
ATG TTG AGC AGC AAG TGA GCC TTC TTG TTT CTC -3′. Mutation 
was confirmed after automatic DNA sequencing (STA B VID A).
Figure 8. Mutating S12 reduces the neurodegen-
erative phenotype of a MJD lentiviral rat model. 
(A) Atx3 72Q–encoding lentiviral particles were 
stereotaxically delivered into rat striata: the left 
hemisphere striatum was injected with atx3 72Q 
WT and the right hemisphere with one of its phos-
phomutants—S12D or S12A. (B and C) Atx3 was 
immunohistochemically (IH) labeled and atx3 ac-
cumulations were quantified. Representative im-
ages of the peroxidase staining of striatal sections 
displaying atx3-positive aggregates are shown. 
Bars, 50 μm. (F and G) Mutating S12 reduces 
the amount of atx3 accumulations caused by atx3 
72Q expression (n = 7 animals injected with atx3 
72Q WT: atx3 72Q S12D; n = 6 animals injected 
with atx3 72Q WT: atx3 72Q S12A; graph bars 
represent mean ± SEM ; Mann-Whitney test: *, P 
< 0.05; **, P < 0.01). (D and E) Neuronal loss 
was assessed by determining the volume of the 
DAR PP-32 immunoreactivity-depleted region in 
each hemisphere. Representative images of the 
peroxidase staining of striatal sections evidencing 
immunoreactivity loss (interrupted line) are shown. 
Bars, 300 μm. (H and I) Mutating S12 of atx3 
reduces the lesion caused by atx3 72Q injection 
into the rat striatum, as evaluated by DAR PP-32 
immunostaining (n = 4 animals injected with 
atx3 72Q WT: atx3 72Q S12D; n = 5 animals 
injected with atx3 72Q WT: atx3 72Q S12A; 
graph bars represent mean ± SEM ; Mann-Whit-
ney test: *, P < 0.05; **, P < 0.01). (J, L, N, 
and P) Excitatory synapse markers PSD -95 and 
VGL UT1 were immunohistochemically labeled 
and imaged in the vicinity of atx3 72Q–express-
ing neurons. Panels show representative confocal 
images of PSD -95 (J and L) and VGL UT1 (N and 
P) punctuate immunostaining. Bars, 5 µm. (K, M, 
O, and Q) The integrated density of PSD -95 and 
VGL UT1 agglomerates is increased in the stria-
tal slices expressing phosphomutated atx3 72Q, 
comparing with slices expressing atx3 72Q WT, 
throughout the range of detection thresholds used 
(n = 3 animals for each injection condition; graph 
bars represent mean ± SEM ; two-way analysis of 
variance detected a P < 0.001 significant differ-
ence between hemispheres).
Figure 9. Phosphorylation of atx3 at S12 counters 
toxic polyQ expansion–derived changes. Atx3 is phos-
phorylated at S12, an amino acid localized in the 
catalytic JD of the protein. Current results suggest that 
this modification decreases the hydrolytic activity of 
atx3 against polyUb chains. S12 phosphorylation in 
atx3 reduces expanded atx3 aggregation, decreases 
dendritic and synaptic loss caused by the expanded 
protein in neurons, and limits neurodegeneration.
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Cell line culture and transfection
HEK 293FT cells were grown in DME M, pH 7.2, supplemented with 
44 mM NaHCO 3, 10% FBS , 0.1 mM nonessential amino acids, 6 mM 
l-glutamine, 1 mM sodium pyruvate, and 500 µg/ml geneticin. COS 
-7 cells were cultured in DME M, pH 7.2, supplemented with 44 mM 
NaCO3, 10% FBS , and 1% penicillin-streptomycin. Both cell lines were 
maintained at 37°C, in a humidified atmosphere containing 5% CO2.
One day before transfection, fully confluent cells were diluted 
(1:6) and seeded onto 100-mm culture plates, and transient trans-
fection was performed after 24 h of cell growth, using the Lipofect-
amine Transfection Reagent for HEK 293FT cells (Life Technologies) 
or the Lipofectamine LTX Transfection Reagent (Life Technologies) 
for COS -7 cells. Expression was left to occur for 24–48  h before 
extracts were prepared.
Viral production
Lentiviral vectors encoding atx3 72Q or shRNA -atx3 were produced 
in HEK 293T cells using the four-plasmid system described previously 
(de Almeida et al., 2002). In brief, HEK 293T cells (cultured as de-
scribed for COS -7 cells) were plated into 100-mm dishes (4 × 106 cells/
dish) and subjected the following day to transient calcium phosphate 
transfection. DNA complexes were formed by mixing 0.5  M CaCl2 
with the DNA constructs (for each plate: 13 µg of the pCMV DR-8.92 
packaging construct, 3.75 µg of pMD2G, 3 µg of pRSV -Rev, and 13 g 
of SIN -W-PGK -ATX 3 72Q WT, S12D or S12A, or shAtaxUNI V), to a 
final concentration of 0.25 M CaCl2. The solution was stirringly mixed 
with an equal volume of Hepes-buffered solution (280  mM NaCl, 
1.5  mM Na2HPO 4, and 100  mM Hepes, pH 7.1), and 1  ml of DNA 
complexes was added to each dish. Cells were incubated at 37°C, in a 
humidified atmosphere containing 3% CO2, for 6 h, after which trans-
fection media was replaced with fresh culture medium. After 48 h of 
culture incubation at 37°C, 5% CO2, the supernatants were collected, 
filtered (0.45 µm Stericup Filter Unit; Merck Millipore), concentrated 
by ultracentrifugation (90 m, 19.000 g, 4°C), and resuspended in PBS 
with 1% BSA . When the viral particles were aimed at animal striatal 
injections, this was followed by another ultracentrifugation step before 
final resuspension in the same solution. The content level of batches 
was assessed by p24 antigen ELI SA (Retrotek HIV -1 p24 Antigen ELI 
SA; Zepto Metrix), and stocks were stored at –80°C.
Immunoprecipitation and mass spectrometry analysis
HEK 293FT cells were stimulated with 20 nM okadaic acid for 16 h, 
5 mM sodium orthovanadate for 30 min, or 200 nM PMA for 20 min. 
Cells were scraped unto immunoprecipitation buffer (20 mM Tris, pH 
7.0, 100 mM NaCl, 2 mM EDT A, 2 mM EGT A, 50 mM NaF, and 1 mM 
Na3VO4), supplemented with 1% Triton X-100, 1 µM okadaic acid, and 
protease inhibitors (1 mM DTT , 0.1 mM PMS F, 10 µg/ml chymosta-
tin, pepstatin, antipain, and leupeptin [CLA P]), sonicated, and cleared 
of the insoluble fraction by centrifugation. 1 mg of protein from each 
extract (1 mg/ml) was used for immunoprecipitation with 3 µg of an-
ti-GFP antibody (clones 7.1 and 13.1; Roche Applied Science). Protein 
samples were eluted with 50 µl SDS -PAG E 2× loading buffer (125 mM 
Tris, pH 6.8, 100 mM glycine, 40% glycerol, 4% SDS , 200 mM DTT 
, and ∼0.01% bromophenol blue). Three samples of each extract were 
subjected to the i.p. procedure, but collectively eluted in sequence.
Immunoprecipitants (100  µl) were alkylated (1% acrylamide, 
20 min) and separated by SDS -PAG E. Online liquid chromatography 
followed by ion spray mass spectrometry analysis of the protein bands 
was performed by the Proteomics Center at the Children’s Hospital 
Boston. Samples were digested in-gel with 12.5 ng/µl trypsin, over-
night, at 37°C, and resulting peptides were extracted with 100 mM am-
monium bicarbonate and acetonitrile and lyophilized. Samples were 
resuspended in 5% acetonitrile, 5% formic acid, and directly injected 
into a liquid chromatography –mass spectrometry system encompass-
ing a microautosampler, a Suvery high performance liquid chromatog-
raphy pump, and a Proteome X (LTQ ) mass spectrometer (all acquired 
from Thermo Finnigan). Peptides were eluted with 0.1% formic acid 
in acetronitrile (30 min linear gradient 8–34% acetonitrile) and applied 
to the mass spectrometer by electrospray ionization. The mass spec-
trometric data obtained were searched against the human international 
protein index database (IPI human 336) using the protein identification 
software Mascot (version 2.2.04; Matrix Sciences), according to the ap-
propriate search criteria necessary for the detection of phosphorylation.
Generation of the anti-Patx3 phosphospecific antibody
Production of the phosphospecific anti-Patx3 antibody was performed 
by Eurogentec. Rabbits were immunized with a phosphorylated atx3-
based peptide—8KQE G-S(PO3H2)-LCA QHC LN20—coupled with the 
keyhole limpet hemocyanin protein carrier. Phosphospecific antibody 
purification was performed on the serum of the best responding animal 
(as evaluated by ELI SA) through affinity chromatography procedures.
Cortical neuron cultures preparation and transfection
Cortices of Wistar rat embryos with 18 d were dissected, trypsinized, and 
resuspended in neuronal plating medium (MEM supplemented with 10% 
horse serum, 0.6% glucose, and 1 mM sodium pyruvate). Cells were 
passed through a 0.2-µm filter and then seeded in high, medium, or low 
density, according to the experimental objectives: high-density cultures: 
9 × 105 cells/well in six-well culture plates coated with poly-d-lysine 
(0.1 mg/ml); medium-density cultures: 2.5 × 105 cells/well onto coated 
15-mm coverslip-containing 12-well culture plates; and low-density cul-
tures (Banker cultures): 3.25 × 105 cells/plate in 60-mm culture plates 
containing coated 18-mm coverslips. For high- and medium-density 
cultures, 2–4 h later, platting medium was substituted by Neurobasal 
medium supplemented with 2% SM1, 0.5 mM glutamine, and 0.12 mg/
ml gentamycin. In the Banker cultures, after 2–3  h, coverslips were 
turned over an astroglial feeder layer (grown in MEM supplemented 
with 10% horse serum, 0.6% glucose, and 1% penicillin-streptomycin) 
and maintained in supplemented Neurobasal medium. Neuronal cultures 
were kept in an incubator at 37°C, with a humidified atmosphere con-
taining 5% CO2, up to 15 days in vitro (DIV ). High- and medium-density 
cultures were fed once a week, and low-density cultures were fed twice 
a week, by replacing 1/3 of the culture medium with fresh medium.
Expression plasmids were transfected by a calcium phosphate 
transfection procedure adapted from a previously described protocol 
(Jiang et al., 2004). In brief, DNA complexes were generated by adding 
2.5 M CaCl2 in 10 mM Hepes drop-wise to the plasmid DNA solu-
tions, for a final concentration of 250 mM CaCl2. High-density cultures 
were transfected at 9–10 DIV cortical neurons using 10 µg of plasmid 
DNA ; medium-density cultures were transfected at 4–5 DIV with 4 
µg plasmid DNA ; and low-density cultures were transfected at DIV 
9–10 with 3 µg DNA . Complexes were mixed with an equal volume 
of Hepes-buffered transfection solution (274 mM NaCl, 10 mM KCl, 
1.4 mM Na2HPO 4, 11 mM dextrose, and 42 mM Hepes, pH 7.2) and 
added to the cultures. Cells were incubated for 1–1.5 h, after which 
transfection medium was substituted by fresh culture medium. Ky-
nurenic acid (2 mM) was used throughout the transfection procedure to 
block ionotropic glutamate receptors. Expression was left to occur for 
a maximum of 5 DIV under normal cell culture incubation conditions.
Atx3 knock-down and neuronal lysate preparation
High-density rat cortical cultures (8 DIV ) were transduced with shRNA 
-atx3–encoding lentiviral particles (20 ng of p24 antigen/105 cells) 
in the presence of 8 µg/ml hexadimethrine bromide. 18  h later, the 
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infection medium was substituted by a mixture of conditioned medium 
and fresh medium (1:2), and expression was left to occur for 6 d under 
normal culture conditions.
Human fibroblast culture
Human fibroblast cells from MJD patients and a matched control were 
obtained from Neurology and Pathology Services, University Hospital 
of Coimbra. Cultures were maintained under 37°C, 5% CO2 incuba-
tion, in DME M, pH 7.2, supplemented with 44  mM NaHCO 3, 10% 
FBS , 0.1 mM nonessential amino acids, 2 mM l-glutamine, 1 mM so-
dium pyruvate, and 1% penicillin-streptomycin.
Cell lysate preparation
Lysates were prepared by scraping cultures onto RIP A buffer (10 mM 
Tris-HCl, pH 7.2, 150 mM NaCl, 5 mM EDT A, 0.1% Triton X-100, 
1% sodium deoxycholate, and 0.1% SDS ), supplemented with protease 
(1 mM DTT , 0.1 mM PMS F, and 10 µg/ml CLA P) and phosphatase 
inhibitors (5 mM NaF, 2 mM Na3VO4, and 1 µM okadaic acid), son-
icated, and freeze-thawed. After, protein quantification samples were 
denatured by adding 5× loading buffer (625  mM Tris-HCl, pH 6.8, 
50% glycerol, 10% SDS , 500  mM DTT , and ∼0.01% bromophenol 
blue) and heating to 95°C.
In vitro activity assays
6His-atx3 produced in BL21(DE3)-SI cells was purified as described 
previously by our group (Gales et al., 2005). Incubation of protein sam-
ples (200 µM) with 0.5 µM Ub-AMC (Boston Biochem) was performed 
in the presence of 20 mM Hepes, pH 7.5, 5% glycerol, and 1 mM EDT 
A, 0.1 mg/ml BSA , and 10 mM DTT , in 96 well plates. Product forma-
tion was assessed at 30°C by fluorescence recording (excitation: 380 
nm; emission: 460 nm). For each technical replicate, initial reaction 
velocity was calculated as the slope of the trend line traced based on 
the fluorescence values (relative fluorescence units) of the first 2 min of 
reaction, after subtraction of the value of the negative control lacking 
6His-atx3 (with an additional 0.2 M BSA ). The obtained velocity values 
were normalized to the mean WT velocity of the respective experiment.
Incubation of the samples (100 nM) with 250 nM K48- or K63-
linked hexameric polyUb chains (Boston Biochem) was performed 
after mixing with 50 mM Hepes, 0.5 mM EDT A, 0.1 µg/ml ovalbumin, 
and 1 mM DTT and left to occur for 20 h, at 37°C. Samples (10 µl) 
were taken from the reaction mixture at 0, 2, 5, and 20 h and immedi-
ately denatured by adding 2× concentrated sample buffer.
SDS -PAG E and Western blot
Equivalent protein amounts of each experimental condition were re-
solved and probed by SDS -PAG E followed by Western blot, performed 
according to standard protocols. Incubation with the primary antibodies 
diluted in 0.5% milk TBS -Tween 20 (TBS -T) was performed for 1–2 h 
at RT or overnight at 4°C, using a mouse monoclonal anti-atx3 antibody 
(1H9, 1:1,000; Millipore), the rabbit polyclonal anti-Patx3 (1:20; pro-
duction described under Generation of the anti-Patx3 phosphospecific 
antibody), a mouse monoclonal anti-actin (β; 1:5,000; Sigma-Aldrich), 
or a rabbit polyclonal anti-Ub (1:1,000; Dako). The appropriate alka-
line phosphatase-conjugated secondary antibodies (goat anti–mouse 
IgG and mouse anti–rabbit IgG; Jackson ImmunoResearch Laborato-
ries) diluted in 0.5% milk TBS -T (1:10,000) were incubated for 1 h at 
RT. In the case of the anti-Patx3 antibody, 5% low-fat dry milk TBS -T 
was used in every step instead.
Dendritic morphology analysis
Transfected cortical neurons (low density) with 14–15 DIV were 
fixed with 4% paraformaldehyde/4% sucrose in PBS for 15 min at RT, 
and coverslips were mounted with Fluorescence Mounting Medium 
(Dako). GFP -atx3–expressing neurons were imaged at RT using an 
Axiovert 200M microscope (CCD monochromatic digital Axiocam 
HRm camera; Axiovision software; Carl Zeiss) and a 20× air objec-
tive (LD-PlanNeofluar, 0.4 NA; Carl Zeiss), and tracing of the cell 
body and dendrites was drawn based on the GFP signal, using the 
Neurolucida software (MBF Bioscience). Sholl analysis and dendritic 
measurement was performed with the Neurolucida Explorer software 
(MBF Bioscience). Total dendritic length of the neurons was normal-
ized to the mean total dendritic length of neurons transfected with 
GFP -atx3 28Q WT, in each independent experiment. For each indi-
vidual experiment, cells were cultured and immunocytochemically 
processed on the same occasion. Dendritic morphology analysis was 
performed blindly to condition.
Synapse quantification
Low-density cultures were fixed asdescribed in the previous para-
graph, permeabilized with 0.25% Triton X-100 in PBS and blocked 
with 10% BSA . Primary antibodies diluted in 3% BSA PBS were 
incubated overnight at 4°C: the mouse monoclonal anti–PSD -95 
(1:200; Affinity BioReagents), the guinea pig polyclonal anti-VGL 
UT1 (1:100,000; Millipore), and the mouse monoclonal anti-gephy-
rin (1:1,000; Synaptic Systems). Coverslips were then incubated with 
the secondary antibodies for 45 min at 37°C: Alexa Fluor 568 anti–
mouse IgG (1:500; Invitrogen) and the Alexa Fluor 647 anti–guinea 
pig IgG (1:500; Molecular Probes). Coverslips were mounted with Flu-
orescence Mounting Medium.
Puncta observation and imaging was performed at RT with an 
Axio Observer Z1 microscope (CCD digital Axiocam HRm camera; 
ZEN Blue software; Carl Zeiss) with a 63× oil objective (Plan-Apo-
chromat, 1.4 NA), after randomly selecting dendritic tracts (min-
imum 10 µm) in GFP -atx3–expressing neurons. Image analysis was 
performed using Fiji software (Schindelin et al., 2012) in manually 
thresholded images. Instances of colocalization of pre- and postsyn-
aptic markers were quantified as functional synapses. Values were nor-
malized per dendritic section length to the mean value of GFP -atx3 
28Q WT in the respective experiment. For each individual experiment, 
cells were cultured and immunocytochemically processed on the same 
occasion, and images were acquired with the same settings. Synapse 
quantification was performed blindly to condition.
Quantification of aggregate-containing neurons
Transfected cortical neurons (medium-density cultures) with 8 DIV 
were fixed as described for the dendritic morpholoy analysis. Count-
ing of GFP -atx3 aggregate-containing neurons was performed blindly 
to condition by manually scanning coverslips and observing the GFP 
fluorescence with a Zeiss Axiovert 200M microscope using a 63× oil 
objective (Plan-Apochromat, 1.4 NA). Aggregation was expressed as 
the fraction of cells with aggregates, normalized to the values obtained 
upon transfection with GFP -atx3 84Q WT, in each experiment.
In vivo lentiviral injections and MJD rat model generation
Adult male Wistar rats (Charles River Laboratories) were anesthetized 
and stereotaxically injected for delivery of lentiviral vectors to the stria-
tum, following the procedure previously described in Alves et al. (2008b). 
For each animal, particles (400,000 ng of p24 antigen, 2 µl, 0.2 µl/min) 
encoding atx3 72Q WT were injected in the left hemisphere and particles 
encoding atx3 72Q S12D or S12A were injected in the right hemisphere.
Animals were housed in a temperature-controlled room and 
maintained on a 12-h light/dark cycle. Food and water were supplied ad 
libitum, and proceedings were executed in accordance with European 
Union Directive 2010/63/EW.
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Rat striatum sample preparation and RT-PCR 
Four weeks after injection, animals were terminally anesthetized with 
80 mg/kg sodium pentobarbital (i.p.), brains were dissected fresh, and 
striatal punches were collected with a Harris Uni-Core pen (2.0-mm 
diameter; Ted Pella). Samples were kept frozen at –80°C.
Tissue punches were thawed at RT, and RNA extraction was per-
formed using the QIA zolTM lysis reagent and the RNeasy Mini kit 
(QIA GEN ), according to the recommended procedure. RNA concen-
tration and purity were determined using the NanoDrop 2000 equip-
ment (Thermo Fisher Scientific). cDNA synthesis was performed 
using the iScript cDNA Synthesis kit (Bio-Rad) from 1 mg of total 
RNA according to the manufacturer’s instructions, and RT-PCR was 
performed with the SsoAdvanced SYB R Green Supermix kit (Bio-
Rad) using predesigned primers (QuantiTect Primer Assays; QIA GEN 
): human atx3 (QT00094927) and human hypoxanthine-guanine phos-
phoribosyltransferase (QT00059066), used as housekeeping gene. 4 µl 
of cDNA diluted 100-fold with DNase free deionized water were used. 
PCR procedure consisted of one cycle at 95°C for 30 s, followed by 45 
cycles of two steps: first at 95°C for 5 s, followed by 15 s at 55°C. The 
melting curve protocol started immediately after the quantitative PCR 
and consisted of 5 s at 65°C, with a 0.5°C temperature increase in each 
step until 95°C was reached. Threshold cycle values were generated 
automatically by the StepOne Software (Applied Biosystems). Stan-
dard curves were generated, and quantitative PCR efficiency was de-
termined by the software. Relative quantification of mRNA levels with 
respect to control samples was determined by the Pfaffl method, taking 
into consideration the different amplification efficiencies of all genes.
Immunohistochemical processing
Four weeks after injection, animals were terminally anesthetized with 
80 mg/kg sodium pentobarbital (i.p.) and transcardially perfused with 
4% paraformaldehyde in PBS , pH 7. Whole brains were removed and 
incubated for 48  h in 20% sucrose PBS . Tissue was then frozen at 
–80°C, and 25-µm coronal sections of the striatal region were prepared 
using a cryostat-microtome (CM3050S; Leica). Slices were stored at 
4°C, free-floating in 0.02% sodium azide PBS until further use.
Immunohistochemical quantitative analysis of atx3 accumulation and 
DAR PP-32 depletion
On the occasion of immunohistochemical labeling, endogenous perox-
idase activity of the slices was inhibited by incubating them with 0.1% 
phenylhydrazine in PBS for 30 min at 37°C. Slices were blocked with 
10% normal goat serum, diluted in 0.1% Triton X-100 PBS for 1–2 h 
at RT and then incubated with the primary antibodies, diluted in block-
ing solution, overnight at 4°C: with the mouse monoclonal anti-atx3 
antibody (1:4,000) or the rabbit polyclonal anti-DAR PP-32 antibody 
(1:5,000; Chemicom). The suitable biotinylated secondary antibody 
(1:200; Vector Laboratories) diluted in blocking solution was incubated 
at RT for 2 h, and signal was developed by incubating slices with the VEC 
TAS TAI N Elite Avidin-Biotin-Peroxidase kit (Vector Laboratories) at 
RT, for 30–40 min, and then with the 3.3′-diaminobenzidine Peroxidase 
Substrate kit (Vector Laboratories). Sections were mounted, dehydrated, 
and finally coverslipped using the Eukitt mounting medium (O. Kindler).
Slices were analyzed and imaged at RT with an Axiovert 200M 
microscope (CCD color digital Axiocam HRc camera; Carl Zeiss), at 
5× (air objective, Fluar, 0.25 NA) and 20× magnifications (air objec-
tive, LD-PlanNeofluar, 0.4 NA). Composite images of complete ag-
gregate-containing or DAR PP-32–depleted regions were automatically 
acquired using the MozaiX function of the AxioVision software.
Quantification of atx3-positive aggregates and determination of 
the area of the DAR PP-32 depletion was made in 7–11 slices for each 
animal, spread over the anterior-posterior extent of the striatum and 
separated by 175 µm. Counting of atx3-positive aggregates was per-
formed on 20×-magnified images of each hemisphere using ImageJ 
(National Institutes of Health). After manually thresholding images so 
that the recognizable atx3-positive accumulations were included in the 
examination, particles >3 µm2 were automatically analyzed and counted 
(scale: 2 pixels/µm), and the estimative calculation of the total number of 
aggregates in the entire striatum was performed as previously described 
(Alves et al., 2008b). When comparing the quantity of aggregates be-
tween the two hemispheres, two percentages were calculated for each 
animal brain, representing the total number of aggregates in one hemi-
sphere as a ratio of the total number of aggregates in the two hemispheres.
Determination of the area of the DAR PP-32–depleted regions 
in the two hemispheres of each slice was performed on 5× images, 
using ImageJ to manually define the regions with decreased antibody 
reactivity and quantify their area (scale: 0.5 pixels/µm). Total depleted 
volume was estimated as previously described (Alves et al., 2008a). 
When comparing the volume of the DAR PP-32–depleted region be-
tween the two hemispheres, two percentages were calculated for each 
animal brain, representing the total volume in one hemisphere as a ratio 
of the sum of the volumes from the two hemispheres.
In both cases, imaging, measurements, and quantifications were 
performed blindly to the hemisphere side.
Immunofluorescence staining of tissue sections and quantitative 
analysis of synaptic markers
Striatal slices were blocked for 1 h with 10% normal goat serum diluted 
in 0.2% Triton X-100 PBS and then incubated at 4°C for 72 h with the 
rabbit monoclonal anti–PSD -95 antibody (1:1,000; Cell Signaling Tech-
nology), the guinea pig polyclonal anti-VGL UT1 antibody (1:1,000; Mil-
lipore), and the mouse monoclonal anti-Myc tag antibody (clone 4A6; 
1:1,000; Millipore), diluted in blocking solution. Sections were incu-
bated overnight with secondary antibodies Alexa Fluor 488 anti–mouse 
IgG, Alexa Fluor 568 anti–rabbit IgG, and Alexa Fluor 647 anti–guinea 
pig IgG (1:500; Life Technologies) diluted in blocking solution, and 
finally mounted and coverslipped using Mowiol 4–88 (Sigma-Aldrich).
Slices were analyzed at RT with a confocal microscope (LSM 
710; Carl Zeiss) using a 63× oil objective (Plan-Apochromat, 1.4 NA; 
QUA SAR detection unit; ZEN Black software). Three-plane confocal 
images (0.053 × 0.053 × 0.67-µm3 voxel size) of regions with homog-
enous punctuate PSD -95 and VGL UT1 signal were acquired in the vi-
cinity of Myc-positive cell bodies from 10–11 slices spread over the 
anterior-posterior extent of the striatum and separated by 175 µm. 5–12 
images were sampled in each hemisphere of each Myc-positive slice. 
Digital image deconvolution was performed using Huygens Essential 
(Scientific Volume Imaging).
Mean integrated density of PSD -95 and VGL UT-1 signals was 
determined at all possible thresholds and divided by total image area 
using an in-house–made macro for the Fiji software (Schindelin et al., 
2012). The custom macro used to determine the mean integrated den-
sity of PSD -95 and VGL UT-1 signals at different thresholds is available 
in the online supplemental material.
Imaging, measurements, and quantifications were performed 
blindly to the hemisphere side.
Nuclear fractionation
Cells were washed with cold PBS and scraped onto buffer 1 (100 mM 
Hepes, 10 mM NaCl, 3 mM MgCl2, 0.1% Triton X-100, and 1 mM 
EGT A, pH 7.5) supplemented with 1 mM, 1 mM PMS F, and 10 µg/
ml CLA P. Extracts were incubated 40 min at 4°C and then centrifuged 
(2.400  g, 10 min, 4°C), supernatants were collected (cytoplasmic 
fraction), and pellets (nuclei) were resuspended in buffer 2 (25  mM 
Hepes, 300 mM NaCl, 5 mM MgCl2, 1 mM EGT A, and 20% glycerol, 
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pH 7.4) supplemented with 1 mM PMS F and 10 µg/ml CLA P. After 
freeze-thawing the nuclei samples three times, they were incubated 1 h 
at 4°C and then centrifuged (12.000 g, 20 min, 4°C), and supernatants 
(nuclear fraction) were collected.
Cytosolic and nuclear fractions were denatured with 5× loading 
buffer and heated, and 40 µg of each sample was analyzed by West-
ern blot as described using a mouse monoclonal anti-FLA G antibody 
(M2, 1:1,000; Sigma-Aldrich). Lamin enrichment of nuclear fractions 
was confirmed on rabbit polyclonal anti-lamin A antibody labeling 
(1:1,000; Sigma-Aldrich). Densitometric analysis of Western blot FLA 
G-atx3 protein bands was performed using ImageJ. Levels of nuclear 
FLA G-atx3 were expressed as the intensity of the nuclear protein 
bands, normalized to the sum of the intensity of these bands and the 
bands of the respective cytosolic fractions.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism 5 soft-
ware (GraphPad Software). Comparison between two conditions used 
the t test (two-tailed) when the values of both samples presented a 
Gaussian distribution or the Mann-Whitney test (two-tailed) in the 
cases where values did not display a normal distribution. Normality 
was assessed through the D’Agostino and Pearson omnibus normal-
ity test. Comparison of samples with a defined value (100%) used 
the one-sample t test. Comparison between more than two conditions 
was achieved with the Kruskal-Wallis test, whereas multiple compar-
isons were performed with two-way analysis of variance, followed by 
Bonferroni post hoc tests.
Online supplemental material
Fig. S1 shows the analysis of dendritic morphology and synapse 
number in cultured rat cortical neurons transfected with GFP -atx3 28Q 
WT and the corresponding empty vector. The Western blot represented 
in Fig. S2 evidences the levels of GFP -atx3 28Q and 84Q WT and the 
S12 phosphomutants in transfected cortical neurons. Fig. S3 compares 
the percentage of aggregate-displaying neurons between cultures 
transfected with GFP -atx3 28Q and 84Q WT and the respective DUB 
inactive C14A mutants. The RT-PCR analysis of atx3 72Q expression 
levels in each lentiviral model rat brain hemisphere is shown in Fig. 
S4. Fig. S5 compares FLA G-atx3 nuclear levels between COS -7 cell 
samples transfected with FLA G-atx3 WT and the S12 phosphomutants. 
Thresholderer is an ImageJ macro developed to analyze different 
immunofluorescence microscopy image parameters, including 
integrated signal density, at consecutive threshold levels. The source 
code for Thresholderer is provided in the online supplemental material. 
Online supplemental material is available at http ://www .jcb .org /cgi /
content /full /jcb .201506025 /DC1.
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Figure S1. Nonexpanded GFP-atx3 causes no neuromorphologic anomalies in transiently transfected cortical neurons. Rat cortical neuron cultures were 
transfected with GFP -atx3 28Q or the empty pEGF P-C1 vector (GFP ). (A) Neurons expressing GFP -atx3 28Q WT display no differences regarding total 
dendritic length (n = 42–47 neurons, from four independent experiments; t test: P > 0.9) or the dendritic arborization profile (B) as evaluated by Sholl 
analysis (n = 42–47 neurons, from four independent experiments; t test: P > 0.05). (C) No differences relative to the number of excitatory synapses (n = 
38–40 neurons, from four independent experiments; t test: P > 0.8) or (D) inhibitory postsynaptic terminals (n = 35–34 neurons, from three independent 
experiments; t test: P > 0.6), were detected. (A–D) Graph bars represent mean ± SEM .
Figure S2. Transfection of rat cortical neurons with GFP-atx3 phosphomutants. Cultured rat cortical neurons with 9–10 DIV were transfected with GFP -atx3 
28Q WT, GFP -atx3 84Q WT, or the respective S12D or S12A mutants, and 5 d later whole-cell lysates were analyzed by Western blot with an anti-GFP 
and an antiactin antibody. The differences in electrophoretic movement between GFP -atx3 28Q and GFP -atx3 84Q reflect the differences in molecular size 
resulting from the distinct number of glutamine residues.
JCB • 2016S18
Figure S3. DUB activity blocking causes no change on expanded atx3 aggregation in cortical neurons. Transfection with the DUB inactive mutant GFP 
-atx3 84Q C14A yields a fraction of neurons with aggregates comparable with what is obtained on transfection with GFP -atx3 84Q WT (50–55 neurons 
counted for each condition in n = 7 independently prepared cultures; graph bars represent mean ± SEM ; one-sample t test: *, P < 0.05).
Figure S4. Expression levels of atx3 72Q in the striatum of the MJD lentiviral rat models. (A and B) RT-PCR analysis of human atx3 mRNA levels revealed 
no significant differences between brain hemispheres (n = 3 animals injected with atx3 72Q WT :atx3 72Q S12D or atx3 72Q WT :atx3 72Q S12A; graph 
bars represent mean ± SEM ; Mann-Whitney test: P > 0.05).
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Figure S5. Mutating S12 does not alter the nuclear accumulation of atx3, in COS-7 cells. (A and B) COS -7 cells were transiently transfected with nonex-
panded (22Q) or expanded (80Q) forms of WT and phosphomutated FLA G-atx3. Cell extracts were subjected to a nuclear fractionation procedure and 
the resulting cytoplasmic and nuclear fractions were analyzed by Western blot to evaluate the relative abundance of FLA G-atx3. Enrichment of lamin in the 
nuclear fractions was used as a control for the fractionation procedure. (C and D) For both expanded and nonexpanded forms of FLA G-atx3, densitometric 
analysis of the blots revealed that the phosphomutants have the same tendency for nuclear accumulation as their nonmutated counterparts (FLA G-atx3 
22Q: n = 3 independent experiments; FLA G-atx3 84Q: five independent experiments; graph bars represent mean ± SEM ; Kruskal-Wallis test: P > 0.05).
Provided online is the source code for Thresholderer, an ImageJ macro developed to analyze different 
immunofluorescence microscopy image parameters, including integrated signal density, at consecutive 
threshold levels.
